alpha-aminopyridine has been researched along with azacitidine in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 5 (41.67) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, X; Jiang, M; Ning, Q; Wang, J; Wang, L; Yao, Y; Yu, L; Zhou, J | 1 |
| Albert, DH; Ansell, P; Arellano, M; Garcia-Manero, G; Kadia, T; Kantarjian, H; Khoury, HJ; Knight, EA; McKee, MD; Munasinghe, W; Oliver, B; Qin, Q; Ricker, JL; Roberts-Rapp, L; Tibes, R; Xiong, H | 1 |
| Garrett-Bakelman, FE; Glass, J; Gliser, C; Intlekofer, AM; Knapp, K; Levine, RL; Mason, CE; Melnick, A; Meydan, C; Nazir, A; Shank, K; Shih, AH; Stein, EM; Straley, K; Thompson, CB; Travins, J; Ward, PS; Yen, K | 1 |
| Chen, K; Deng, M; Guo, X; Jiang, Z; Li, P; Shi, P; Xu, B; Zha, J; Zhang, L | 1 |
| Fan, Y; Guo, F; Song, D; Sun, Q; Wang, J; Wang, L; Zhang, D; Zhang, Q; Zhang, W | 1 |
| Hoffmann, M; Surapaneni, S; Tong, Z; Yao, S; Yerramilli, U; Young, JD | 1 |
| Estey, EH; Percival, MM | 1 |
| Naoe, T | 1 |
| Avanzino, B; Chopra, VS; DiMartino, JF; Figueroa, ME; MacBeth, KJ; Quek, L; Schwickart, M; See, WL; Tang, L; Zheng, B | 1 |
| Bennett, JM; de Botton, S; DiNardo, CD; Döhner, H; Fathi, AT; Frattini, MG; Gong, J; Hasan, M; Kantarjian, HM; Lersch, F; Martin-Regueira, P; Montesinos, P; Schuh, AC; Stein, EM; Vyas, P; Wei, AH; Zeidan, AM | 1 |
| Fu, JH; Li, JL; Li, Z; Qiu, HY; Qiu, QC; Xue, SL; Zhang, J; Zhou, M | 1 |
| Al Jammal, M; Al-Juhaishi, T; Al-Kindi, SG; Arora, S; Badhwar, A; Chahine, N; Chami, T; Hajjari, J; Heisler, AC; Hoit, BD; Janus, SE; Mously, H | 1 |
3 review(s) available for alpha-aminopyridine and azacitidine
| Article | Year |
|---|---|
Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia.
Topics: Aminopyridines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Azacitidine; Cytogenetic Analysis; Decitabine; Enzyme Inhibitors; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunologic Factors; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Diagnostic Techniques; Neoplasm, Residual; Nivolumab; para-Aminobenzoates; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines; Recombinant Fusion Proteins; Remission Induction; Transplantation, Homologous; Triazines; Triazoles | 2019 |
＜Editors' Choice＞ How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement.
Topics: Aged; Aged, 80 and over; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Arsenic Trioxide; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; fms-Like Tyrosine Kinase 3; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Phenylurea Compounds; Precision Medicine; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Smoothened Receptor; Staurosporine; Sulfonamides; Survival Rate; Tretinoin; Triazines | 2020 |
Reported Pericardial Toxicities Associated with Acute Myelogenous Leukemia Treatments: A Pharmacovigilance Analysis of the FDA Adverse Reporting Database.
Topics: Adolescent; Adult; Aminopyridines; Anthracyclines; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Cytarabine; Decitabine; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Pericarditis; Pharmacovigilance; Sulfonamides; Triazines; United States; United States Food and Drug Administration | 2022 |
2 trial(s) available for alpha-aminopyridine and azacitidine
| Article | Year |
|---|---|
Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.
Topics: Aged; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinases; Azacitidine; Female; Hematologic Neoplasms; Humans; Male; Maximum Tolerated Dose; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor | 2015 |
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
Topics: Aged; Aminopyridines; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Mutation; Progression-Free Survival; Random Allocation; Treatment Outcome; Triazines | 2021 |
7 other study(ies) available for alpha-aminopyridine and azacitidine
| Article | Year |
|---|---|
Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.
Topics: Aminopyridines; Antigens, Neoplasm; Apoptosis; Azacitidine; Benzamides; Blotting, Western; Cell Cycle; Cell Line, Tumor; Decitabine; Flow Cytometry; Histone Deacetylase Inhibitors; HLA-A Antigens; Humans; Leukemia, Myeloid, Acute; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocytes, Cytotoxic | 2013 |
Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dioxygenases; DNA Methylation; DNA-Binding Proteins; Epigenesis, Genetic; fms-Like Tyrosine Kinase 3; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mice; Mice, Mutant Strains; Molecular Targeted Therapy; Mutation; Proto-Oncogene Proteins; Signal Transduction; Triazines | 2017 |
Low-dose decitabine enhances chidamide-induced apoptosis in adult acute lymphoblast leukemia, especially for p16-deleted patients through DNA damage.
Topics: Adolescent; Adult; Aminopyridines; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Benzamides; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Damage; Female; Gene Deletion; Histone Deacetylase Inhibitors; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Young Adult | 2017 |
Hypermethylated CD36 gene affected the progression of lung cancer.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; CD36 Antigens; Cell Line, Tumor; Cell Movement; Cell Proliferation; Decitabine; Disease Progression; DNA Methylation; Down-Regulation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Neoplasm Invasiveness; Xenograft Model Antitumor Assays | 2018 |
Topics: Aminopyridines; Animals; Azacitidine; Cell Line; Humans; Isocitrate Dehydrogenase; Nucleoside Transport Proteins; Triazines; Xenopus laevis | 2019 |
Combination of azacitidine and enasidenib enhances leukemic cell differentiation and cooperatively hypomethylates DNA.
Topics: Aminopyridines; Azacitidine; Cell Line, Tumor; DNA Methylation; DNA, Neoplasm; Humans; Leukemia, Myeloid, Acute; Triazines | 2021 |
Epigenetic therapy with chidamide alone or combined with 5‑azacitidine exerts antitumour effects on acute myeloid leukaemia cells
Topics: Aminopyridines; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Benzamides; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Synergism; Epigenomics; Humans; Leukemia, Myeloid, Acute; U937 Cells; Up-Regulation | 2022 |